Dr. Sawyer on LBM Outcomes With Siltuximab in Multicentric Castleman's Disease

Michael Sawyer, MD
Published: Tuesday, Aug 26, 2014

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman’s disease who received siltuximab (Sylvant).

Interleukin-6 (IL-6) plays a pivotal role in both multicentric Castleman’s disease and cachexia (loss of weight, muscle atrophy, fatigue, weakness). In this study, the mean maximal gain in LBM in the siltuximab-treated patients was 2.4 kg compared with 1.1 kg in those receiving placebo.

Further, Sawyer says, greater than 50% of patients treated with siltuximab gained more than 1 kg of LBM at first CT exam at 9 weeks. At no point did patients receiving placebo reach that level.

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman’s disease who received siltuximab (Sylvant).

Interleukin-6 (IL-6) plays a pivotal role in both multicentric Castleman’s disease and cachexia (loss of weight, muscle atrophy, fatigue, weakness). In this study, the mean maximal gain in LBM in the siltuximab-treated patients was 2.4 kg compared with 1.1 kg in those receiving placebo.

Further, Sawyer says, greater than 50% of patients treated with siltuximab gained more than 1 kg of LBM at first CT exam at 9 weeks. At no point did patients receiving placebo reach that level.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x